Clinical Trials Logo

Clinical Trial Summary

The study aimed at evaluating whether current 24 weeks length of combination treatment is appropriate or not for patients with HCV genotype 3 infection.


Clinical Trial Description

Patients are randomized to standard length of treatment or to a variable duration: 12 weeks for patients with undetectable HCVRNA at week 4 or 24 or 36 weeks for those with detectable HCV RNA at week 4. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01121705
Study type Interventional
Source Casa Sollievo della Sofferenza IRCCS
Contact
Status Completed
Phase Phase 3
Start date January 2007
Completion date June 2009

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01833611 - Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Phase 4
Completed NCT00771446 - Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency Phase 1/Phase 2
Active, not recruiting NCT03731923 - Abbreviated MRI for HCC Surveillance N/A
Recruiting NCT03013556 - Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients Phase 4
Recruiting NCT05181826 - Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Active, not recruiting NCT02143180 - Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study N/A
Completed NCT00596414 - Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial Phase 4
Active, not recruiting NCT02772003 - DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Phase 1
Terminated NCT04775797 - Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection Phase 1
Terminated NCT03487848 - Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection Phase 2
Recruiting NCT02822079 - DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Phase 1
Recruiting NCT04446832 - VACcination of LIver Transplantation Candidates
Completed NCT02742597 - Patient-Centred Innovations for Persons With Multimorbidity - Ontario N/A
Completed NCT05678582 - Hepatic Steatosis and Chronic Hepatitis B Virus
Not yet recruiting NCT05062967 - Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
Completed NCT01380938 - Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) Phase 3
Recruiting NCT01413360 - The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients Phase 4
Terminated NCT00496158 - Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus Phase 3
Terminated NCT00496002 - Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus Phase 3
Completed NCT02789800 - Patient-Centred Innovations for Persons With Multimorbidity - Quebec N/A